MultiSeq is a Pioneer — making DNA sequence-based molecular diagnostics routinely available with syndromic panels for both Point-of-Care and high-volume testing.
MultiSeq test panels are based on a combination of one or more patented, proprietary technology platforms. They provide comprehensive, confirmatory, cost-effective results for timely clinical intervention.
Differentiators
- Accuracy.
- Modified Sanger sequencing.
- Verifiable result format (nucleotide sequence)
- Multiple pathogens per multiplexed panel (up to 20 targets)
- Variety of comprehensive syndromic panels
- Cost-effectiveness
- Quality Control with intrinsic nucleotide-based barcodes
- Novel true internal control to ensure no false negative results.
- Monitoring of contamination to ensure no false positive results.
- Sample ID
- Operational
- Menu niche of 1- 20 pathogens per panel
- Quantification
- Detection of variants:
- New viral variants of pandemic significance
- Viral mutations causing vaccine resistance
- Gain/loss of function
- Prediction of antibiotic sensitivity